Table 1.

Characteristics of SJLIFE participants and nonparticipants

Nonparticipants (n = 1,673)Participants (n = 3,016)Only one SJLIFE visit (n = 1,831)Multiple SJLIFE visits (n = 1,185)
n (%)n (%)Pan (%)n (%)Pb
Sex
 Male977 (58.4)1,576 (52.3)<0.0001981 (53.6)595 (50.2)0.07
 Female696 (41.6)1,440 (47.8)850 (46.4)590 (49.8)
Race
 Non-Hispanic white1,361 (81.4)2,491 (82.6)0.661,485 (81.1)1,006 (84.9)<0.0001
 Non-Hispanic black261 (15.6)432 (14.3)270 (14.8)162 (13.7)
 Non-Hispanic other20 (1.2)33 (1.1)23 (1.3)10 (0.8)
 Hispanic31 (1.9)60 (2.0)53 (2.9)7 (0.6)
Age at assessment, y
 18–291,386 (46.0)971 (53.0)415 (35.0)<0.0001
 30–391,093 (36.2)610 (33.3)483 (40.8)
 40–49453 (15.0)206 (11.3)247 (20.8)
 ≥5084 (2.8)44 (2.4)40 (3.4)
 Mean (SD) age at assessment, y31.93 (8.44)30.58 (8.28)34.03 (8.26)<0.0001
Age at diagnosis, y
 0—4628 (37.5)1,131 (37.5)0.91726 (39.7)405 (34.2)<0.0001
 5—9401 (24.0)710 (23.5)441 (24.1)269 (22.7)
 10—14366 (21.9)686 (22.8)411 (22.5)275 (23.2)
 ≥15278 (16.6)489 (16.2)253 (13.8)236 (19.9)
Time since diagnosis, y
 10—191,160 (38.5)809 (44.2)351 (29.6)<0.0001
 20—291,163 (38.6)674 (36.8)489 (41.3)
 30–39590 (19.6)293 (16.0)297 (25.1)
 ≥40103 (3.4)55 (3.0)48 (4.1)
Primary diagnosis
 Leukemia585 (35.0)1,123 (37.2)0.02695 (38.0)428 (36.1)<0.0001
 CNS tumor171 (10.2)308 (10.2)185 (10.1)123 (10.4)
 Hodgkin lymphoma180 (10.8)361 (12.0)147 (8.0)214 (18.1)
 Non-Hodgkin lymphoma149 (8.9)221 (7.3)158 (8.6)63 (5.2)
 Neuroblastoma71 (4.2)138 (4.6)84 (4.6)54 (4.6)
 Wilms tumor117 (7.0)198 (6.6)121 (6.6)77 (6.5)
 Soft tissue sarcoma56 (3.4)82 (2.7)63 (3.4)19 (1.6)
 Bone tumor154 (9.2)312 (10.3)170 (9.3)142 (12.0)
 Retinoblastoma43 (2.6)90 (3.0)55 (3.0)35 (3.0)
 Germ cell tumors57 (3.4)67 (2.2)51 (2.8)16 (1.4)
 Other solid tumor90 (5.4)116 (3.9)102 (5.6)14 (1.2)
Treatment exposure
 Any radiation876 (52.4)1,768 (58.6)<0.0001945 (51.6)823 (69.5)<0.0001
 Chest radiation459 (27.4)882 (29.2)0.19412 (22.5)470 (39.7)<0.0001
 Cranial radiation520 (31.1)1,053 (34.9)0.01594 (32.4)459 (38.7)0.0004
 Abdominal/pelvic radiation398 (23.8)739 (24.5)0.59361 (19.7)378 (31.9)<0.0001
 Any chemotherapy1,388 (83.0)2,587 (85.8)0.011,555 (84.9)1,032 (87.1)0.10
 Anthracyclines932 (55.7)1,768 (58.6)0.051,083 (59.2)685 (57.8)0.46
 Alkylating agents1,011 (60.4)1,903 (63.1)0.071,109 (60.6)794 (67.0)0.0003
 Platinum210 (12.6)373 (12.4)0.85231 (12.6)142 (12.0)0.61
 Glucocorticoids751 (44.9)1,431 (47.5)0.09869 (47.5)562 (47.4)0.99
 Epipodophyllotoxins564 (33.7)1,128 (37.4)0.01735 (40.1)393 (33.2)0.0001
 Antimetabolites844 (50.5)1,586 (52.6)0.16982 (53.6)604 (51.0)0.15
 Nephrectomy120 (7.2)226 (7.5)0.69138 (7.5)88 (7.4)0.91
BMI, kg/m2
 <18.5111 (3.7)67 (3.7)44 (3.7)0.56
 18.5–24.91,001 (33.2)627 (34.2)374 (31.6)
 25.0–29.9845 (28.0)505 (27.6)340 (28.7)
 30.0–39.9829 (27.5)499 (27.3)330 (27.9)
 ≥40.0228 (7.6)131 (7.2)97 (8.2)
 Unable to determine2 (0.1)2 (0.1)
Smoking status
 Never smoked1,930 (64.0)1,153 (63.0)777 (65.6)0.006
 Former smoker338 (11.2)184 (10.1)154 (13.0)
 Current smoker704 (23.3)454 (24.8)250 (21.1)
 Unknown44 (1.5)40 (2.2)4 (0.3)
  • Abbreviation: CNS, central nervous system.

  • aCompare participants to nonparticipants.

  • bCompare participants with multiple visits to participants with only one visit.